Study Summary
Clinical Trial for the safety and efficacy of CD19-BAFF CAR-T cells therapy for refractory/relapsed B-cell acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma.
Want to learn more about this trial?
Request More InfoInterventions
CD19-BAFF Targeted CAR T-cellsBIOLOGICAL
Each subject receive CD19-BAFF Targeted CAR T-cells by intravenous infusion
Study Locations
| Facility | City | State | Country |
|---|---|---|---|
| The first affiliated hospital of medical college of zhejiang university | Hangzhou | Zhejiang | China |